HIV associated with increased risk of MDR-TB

Michael Carter
Published: 05 February 2014

HIV infection is associated with an increased risk of multi-drug-resistant tuberculosis (MDR-TB), results of a systematic review and meta-analysis published in PLOS ONE show. HIV increased the risk of MDR-TB by 24%. The analysis included 24 separate studies with a total patient population of 93,000. The investigators believe their findings have important implications for TB control programmes in terms of detection, appropriate treatment, infection control and follow-up.

“According to the results of this meta-analysis the odds of having MDR-TB among HIV-positive cases was higher by 24% and this was significant as pooled,” write the authors.

Globally, TB is among the leading causes of serious illness and death in people with HIV. TB treatment outcomes can be excellent in HIV-positive patients, but the treatment and control of TB is complicated by the growing epidemics of MDR-TB and extensively drug-resistant TB (XDR-TB).

MDR-TB involves resistance to the key first-line drugs isoniazid and rifampicin. It is unclear if HIV infection is associated with an increased risk of MDR-TB. Investigators from Ethiopia therefore conducted a systematic review and meta-analysis of studies exploring the relationship between the two infections. Cross-sectional, surveillance, case-control and cohort studies were eligible for inclusion.

Over 1000 abstracts were scrutinised  and a total of 24 studies met their inclusion criteria. These studies were conducted between 1990 and 2011 and included 14 cross-sectional studies, seven case-control studies, two surveillance reports and one cohort study. Study populations ranged from 172 to 56,000. The studies were conducted in 16 countries in six world regions.

Pooled results showed that HIV was associated with an increased risk of MDR-TB (OR = 1.24; 95% CI, 1.04-1.43).

Seven studies reported on the interaction between HIV infection and the risk of primary MDR-TB. Their pooled results showed that HIV was associated with a more than two-fold increase in risk (OR = 2.28; 95% CI, 1.52-3.04). There was a non-significant association between HIV and the risk of secondary MDR-TB (OR = 1.02; 95% CI, 0.80-1.24).

The association between HIV infection and risk of MDR-TB was significant in cross-sectional/surveillance studies (OR = 1.26; 95%CI, 1.02-1.49).  As regards study base, the interaction between HIV and MDR-TB was significant in population-based studies (OR = 1.38; 95% CI, 1.09-1.66) and just short of significance in institution-based research (OR = 1.20; 95% CI, 0.96-1.43).

The authors urge that their findings should be “interpreted in the context of both inherent limitation of the original studies and the current review and meta-analysis.”

Nevertheless, they believe their findings have implications for TB control and treatment programmes.

“Capacity for diagnosis of MDR-TB and initiating and scale up of antiretroviral treatment, and collaboration between HIV and TB control programs needs to be considered and strengthened,” conclude the authors. “Good infection control programs need to be implemented.”


Mesfin YM et al. Association between HIV/AIDS and multi-drug resistant tuberculosis: a systematic review and meta-analysis. PLOS ONE 9(1): e82235, 2014.

This news report is also available in Russian.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.